We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable a-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks.
Introduction
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are common medical conditions that increase with age and can have a negative impact on the quality of life in aging men. 1, 2 In addition to the epidemiological evidence of the comorbidity of BPH/LUTS and ED, recent studies revealed that there might be a common pathophysiological mechanism between these two diseases so that the treatments for BPH and ED could interact. 3, 4 The mechanism for this relationship is unclear, but some possibilities have been suggested, such as mechanisms involving nitric oxide, autonomic hyperactivity and the Rho-associated kinase activation/endothelin pathway. 5 a 1 -Adrenergic blockers (a 1 -blockers) are considered to provide the most effective pharmacotherapy for patients with BPH/LUTS, and the phosphodiesterase type 5 (PDE-5) inhibitors are the first-line treatment for patients with ED. 6, 7 Although the safety and efficacy of both a 1 -blockers and PDE-5 inhibitors are well established individually and have been prescribed with minimal limitations related to side effects, there are few reports regarding the safety and efficacy of coadministering both types of agents. [8] [9] [10] [11] Moreover, the pharmacotherapy of both PDE-5 inhibitors and a-blockers has the same potential side effects associated with the hemodynamic status and the cardiovascular system, hence it is important that concerns regarding the potential hemodynamic consequences of the simultaneous administration of a 1 -blockers and PDE-5 inhibitors are addressed. When considering the characteristics of aging patients with a high prevalence of comorbidity with other cardiovascular risk factors (for example, hypertension and diabetes mellitus), the possibility of cardiovascular side effects related to the coadministration of these agents is of ethical concern for the physician. There have been several recent reports regarding the safety of coadministering a 1 -blockers and PDE-5 inhibitors, focusing on their influences on the cardiovascular system and blood pressure (BP). 3, 12, 13 However, more data are needed from large-scale clinical trials if we are to establish the safety and efficacy of such a combined therapy. Udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrolli dinyethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1, 6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one; Zydena, Dong-A Pharmaceutical Company, Seoul, Korea) is a novel, potent PDE-5 inhibitor having a similar molecular structure to sildenafil citrate (Viagra). It is one of the most widely prescribed PDE-5 inhibitors in Korea. 10, 14, 15 In this study, we evaluated the clinical efficacy and safety of coadministered PDE-5 inhibitors and an a 1 -blocker in patients with both BPH/LUTS and ED, using udenafil in patients already receiving stable a1-blocker therapy.
Patients and methods

Study design
This trial was an open, prospective, non-comparative study conducted in two urology centers in Korea (the Yongdong Severance hospital of Yonsei University Health System and The Holy Family Hospital of Catholic University of Korea) from January 2007 to March 2008. The enrolled patients were observed at baseline (Visit 1: V1), and at 4 (V2) and 8 (V3) weeks after medication with udenafil. They were diagnosed with BPH/LUTS and were undergoing stable a1-blocker therapy at least 12 weeks or more before being enrolled to this trial and being administrated udenafil. There was no limitation to enrollment depending on the individual kind of a 1 -blocker prescribed earlier (doxazosin, tamsulosin or alfuzosin). At baseline, systolic BP (SBP)/ diastolic BP (DBP) and heart rate (HR) of all patients were checked. If risk factors of cardiovascular disease, such as hypertension, diabetic mellitus and cerebrovascular disease were present, electrocardiography was taken as the optional evaluation. In addition to the routine check-up of the hemodynamic parameters, all patients were asked to complete the international prostatic symptom score (IPSS) and international index of ED (IIEF-5) as the baseline evaluation of the severity of BPH/LUTS and ED. After enrollment, the clinical parameters (SBP/DBP, HR, IPSS and IIEF-5) were evaluated at every visit. The patients were asked to take udenafil at least once a week during the study period regardless of sexual intercourse, but were warned never to exceed one in a day. The interval of coadministration between the a 1 -blocker and udenafil was 6 h or more. We provided a personal diary in which all patients noted the date of taking udenafil and any health-related events that occurred after medication of udenafil. Keeping a check on the clinical parameters, all patients were interviewed by the investigator to evaluate any adverse event related to the treatment or any other changes in health-related issues that were mentioned in the personal diary.
This study protocol was reviewed and approved by the Institutional review board, and was performed in accordance with good clinical practice guidelines. Each patient provided his written informed consent before enrollment in the trial.
Patients
Patients who were eligible to enroll in this study were men who met the following criteria at the initial visit (V1): 50 to 70 years of age, earlier diagnosed BPH and undergoing stable pharmacotherapy by any kind of a 1 -blocker without adverse events related to the medication for more than 12 weeks, related to IPSS for 9 or more weeks and, related to IIEF-5 for 21 or less weeks. Patients were excluded if they had a history of hypersensitivity to any kind of PDE-5 inhibitor; history of an earlier medication of any kind of PDE-5 inhibitor within 12 weeks from enrollment; history of symptomatic hypotension; history of severe cardiovascular or cerebrovascular disease; severe renal or liver disease; or uncontrolled hypertension with or without history of cardiac-related surgery. Patients who were taking medication that might have affected the clinical parameters or were contraindicative to coadministration with a 1 -blockers or PDE-5 inhibitors, such as nitrate, inhibitors or inducers of CYP3A4, androgen or 5-a-reductase inhibitors, were also excluded in this trial.
Clinical variables
The SBP/DBP and HR changes were evaluated during the study periods. The primary pharmacodynamic end point was the mean change of BP and HR during this time. In the study periods, all patients were observed every 4 weeks and their BP and HR were repeatedly checked. The clinical efficacy of the coadministration of udenafil and a 1 -blocker was also evaluated on every visit by the mean change of IPSS and IIEF-5. An outlier analysis was performed to evaluate whether the personal history of hypertension or the history of an earlier PDE-5 inhibitor medication would influence the hemodynamic parameters. For this outlier analysis, the patients were divided according to the personal history of hypertension or PDE-5 inhibitor medication history at the end point of the trial.
Safety
The criteria for safety evaluation included adverse events, laboratory results, vital signs and electroSimultaneous administration of udenafil and an a-blocker in men with ED BH Chung et al cardiography if available. Any patient who took at least one dose of udenafil and who had posttreatment safety data were considered eligible.
Statistical analysis
Efficacy was analyzed at the end point in the intentto-treat population. The change from baseline in the scores for IPSS, IIEF-5 and each parameter related to cardiovascular adverse events was analyzed using a paired Student's t-test. Safety was analyzed in the exposed population. All statistical tests were two sided.
Results
Of the 120 men (mean age 58.4 ± 5.7 years), 82 (68.3%) completed enough of the trial to be evaluated. The mean number of udenafil taken was 2.2 times per week (range 0-5) in the intent-to-treat group. Four patients dropped out at V2 because of adverse events, such as hot flushes (n ¼ 2), headache (n ¼ 1) and nonspecific chest discomfort (n ¼ 1). Among these patients, those with hot flushes and headaches were found to be receiving medication for hypertension. The patient with chest discomfort had no history of other diseases. Most of the other patients who did not complete the trial did so because they withdrew consent (n ¼ 7), were lost to follow up (n ¼ 15) or because the clinical data were lost or incomplete (n ¼ 2). Ten other patients did not use an adequate dose of udenafil between the visits (at least once in a week), according to the study protocol.
The adverse effects are shown in Table 1 ; 28 and 16 patients reported one or more adverse events at V2 and V3, respectively. Among the 28 patients who reported adverse events at V2, 12 also reported one or more adverse events at V3. Of the 16 patients who reported adverse events at V3, four had no experience of adverse events until V2. There were 46 adverse events at V2 and 26 at V3. The common adverse events were hot flushes, headaches and a sensation of fever. However, except for the four patients mentioned above, all adverse events were minimal and self-limiting. There was no serious adverse event reported during the study and no evidence of severe hypotension or syncope.
Changes in the mean SBP and DBP values during the trial are shown in Figure 1a Similarly, an earlier medical history of using The clinical efficacy of coadministration of an a 1 -blocker and udenafil was evaluated by changes in the IPSS and IIEF-5 scores. The IIEF-5 scores on V1, V2 and V3 were 11.9, 17.3 and 19.3, respectively, and this improvement was statistically significant (Po0.01 V1 vs V2, Po0.01 V1 vs V3; Figure 2 ). In addition to this improvement in the patients' perception of sexual dysfunction, there was also a significant improvement in the LUTS determined by IPSS (Figure 3 ). The IPSS scores at V2 and V3 were 11.7 and 11.5, respectively. When comparing these with the initial IPSS score of 14.3, the improvement in LUTS score was statistically significant (Po0.05).
Discussion
As emerging evidence about the confirmative relationship between LUTS and ED, PDE-5 inhibitors, which are traditionally used to treat ED, have shown the possibility of improving LUTS in recent studies. [16] [17] [18] According to earlier studies, sildenafil, vardenafil and tadalafil had all shown clinical effects on LUTS as well as ED and were well tolerable. Although earlier trials were designed as experimental protocol of continuous administration of PDE-5 inhibitors and had hurdles to being widely accepted in real practice, the possibility of PDE-5 as a new agent in the management of LUTS/BPH is increasing in popularity. With aging population and increases in interrelated medical conditions, there is growing interest in evaluating the safety and efficacy of coadministering a-blockers and PDE-5 inhibitors in patients with LUTS and ED. 3, 4, 13, 19 The individual efficacy rates of both a-blockers and PDE-5 inhibitors are well established in patients with LUTS and ED, but their effects in combination have been investigated only recently. According to a pharmacological study using organ bath culture, the combination of tadalafil and alfuzosin has an additive relaxant effect on inhibiting human corpus cavernosal contraction. 20 Moreover, in a recent pilot study, 62 men with LUTS and ED were randomized to alfuzosin (10 mg, OD), sildenafil (100 mg, OD) or to a combination of both agents. There were significant improvements in efficacy in all three groups, but the combination treatment group had the most benefits. 21 In our study, there was a similar additional improvement in LUTS after the coadministration of udenafil compared with baseline, which was a period of a-blocker monotherapy. However, this trial had some limitations with regard to the study design; thus, the interpretation of the results should consider these limitations. One of the limitations of this study is the lack of a placebo control group. As there was no placebo control group, the factors related to patients' motivation and placebo effect had to be completely excluded. In addition to the placebo effect, we also could not completely exclude the possibility of bias in these results, as the patients did not take udenafil regularly. When considering the pharmacological half-life of udenafil, it is not clear whether the improvement in LUTS in this study was really related to this drug. Regardless of the limitation of being a non-comparative and intermittent administration design, in our knowledge, this study is the first large-scale clinical trial that suggests a clinical benefit for the coadministration of a-blockers and PDE-5 inhibitors in patients with BPH/LUTS and ED. Also, as the intermittent, on demand administration of udenafil is closely related to real practice, our results could Figure 3 The changes of the international prostatic symptom score (IPSS) over 8 weeks of treatment with PDE-5 inhibitors and a-blocker. PDE-5, phosphodiesterase type 5.
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provide clinical evidence about the efficacy of the coadministration of the drugs, not in the experimental condition but, in real practice. Moreover, the authors believed that the mean number of the medicine taken during the trial, 2.2 tablets a week, was not insufficient for the first step of the conclusion. The lack of objective parameters of LUTS, such as uroflowmetry, is another limitation of this study, as we evaluated only the subjective parameter, IPSS. As LUTS and ED are believed to be linked, not only through pathological mechanisms but also in psychological aspects, 22 one hypothesis for interpreting these improvements is that the improved erectile function could have led to an improvement in the patient's quality of life, causing some confusion about the actual improvement of voiding symptoms. More evidence from clinical trials will be needed to clarify the relationships between the coadministration of both drugs and improvements in LUTS.
Adverse hemodynamic effects arising from the medical treatment of patients with BPH and ED are the most common-and sometimes seriousproblems faced in practice. The individual effects of treatments on the cardiovascular system are well established and many guidelines have been proposed relating to the interaction between a-blockers or PDE-5 inhibitors and other cardiovascular agents. 23, 24 However, there are only limited data on any cardiovascular side effect of the coadministration of both agents. 25 A placebo-controlled trial in 22 patients with BPH and ED reported that the combined treatment of tadalafil and tamsulosin did not lead to clinically significant hypotension and caused no serious adverse events. 12 On the other hand, one report suggested significantly increased adverse cardiovascular events, especially with non-selective a 1 -blockers. 13 In this study, none of the cardiovascular parameters showed any clinically significant change. Moreover, comorbidity with hypertension had no effect on adverse cardiovascular effects. However, as monitoring of BP and HR values was not conducted after the 'real' administration of the drugs or with a consideration of washout times, our interpretation of the results may need more discussions. This trial had a limitation in determining the 'real-time' influence on BP and HR in the coadministration of a-blockers and udenafil because we could not evaluate the change of BP and HR immediately after administration of the drugs. Thus, when we considered the action time of udenafil and the interval between the time of administration and visit, the results regarding the safety of the coadministration of the a-blocker and udenafil established by this trial had limitations. However, inspite of all the mentioned limitations, this trial still had important clinical significance considering that this trial could reflect the clinical safety of the coadministration of an a-blocker and udenafil in 'real practice'. The authors believe that the tolerability of the adverse events related to the hemodynamic change in this trial could 'indirectly' guarantee the safety of the coadministration of a-blocker and udenafil. There were only limited data regarding the direct and real-time effect on BP and HR from the large-scale patients' groups. For a confirmative evaluation of its effect on BP and HR, more trials that include the consideration of 'real-time' influence will be needed.
In this study, we used the new PDE-5 inhibitor, udenafil. There are five different PDE-5 inhibitors available in Korea. In addition to worldwide agents such as sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra), there are two additional PDE-5 inhibitors developed individually by a Korean pharmaceutical company: udenafil (Zydena) and mirodenafil (Mvix). Udenafil has a pharmacokinetic profile in that its T max is about 1-1.5 h and its T 1/2 is about 11-13 h. 26, 27 The clinical effect of udenafil is known to prolong for 24 h or more in clinical practice. Therefore, udenafil is similar to sildenafil and vardenafil, as it leads to rapid onset of action, and is similar to tadalafil in terms of its long duration of efficacy. The efficacy and safety of udenafil have been shown to be similar to those of the other PDE-5 inhibitors. 10, 15, 28 Although udenafil is one of the most popular agents for treating ED in Korea, it is not yet available outside Korea, although phase IIa and III trials have been conducted in the United States since 2006. This is the first report showing that udenafil has similar safety and efficacy to other PDE-5 inhibitors when coadministered with a-blockers.
One important point of this study is its unique inclusion criteria. As mentioned earlier, all enrolled patients were diagnosed with BPH/LUTS and were undergoing stable a-blocker therapy for at least 12 weeks. There are many side effects and parameters that can influence the safety of the treatment when comparing PDE-5 inhibitors and a-blockers, and the side effects on the cardiovascular system evaluated in this study are the most typical. Owing to these common points, the causes of any side effects may be unclear, and the interpretation of the results may be biased. Earlier studies on the efficacy and safety of a-blockers reported that stable therapy is established within 8 or 12 weeks from first administration. In addition, significant side effects related to a-blocker therapy were reported within the same period, and there were few new side effects that developed later than 12 weeks from the time of first administration. 8, 29 Therefore, we assumed that the enrolled patients were free from side effects related to a-blocker monotherapy, and that any side effect that developed after the coadministration of both drugs was caused by the PDE-5 inhibitors independently.
The withdrawal rate of this study was 31.7% (38/120), and this was higher than expected when considering its relatively simple design. The most Simultaneous administration of udenafil and an a-blocker in men with ED BH Chung et al common causes of withdrawal were loss to followup (n ¼ 15), inadequate medication (n ¼ 10) and withdrawal of consent (n ¼ 7). As only four patients withdrew because of adverse events, one possible cause of the relatively high withdrawal rate was patients' preconceptions about the use of PDE-5 inhibitors in aging men in Korea and a failure to understand the nature of the trial. The incidence of adverse events was similar to earlier reports on monotherapy using PDE-5 inhibitors in patients with ED, or with monotherapy using a-blockers in patients with BPH/LUTS. 8, 28, [30] [31] [32] Thus, the coadministration of udenafil and a-blockers did not elevate the incidence of such adverse events, so the therapy appears safe.
Conclusions
The coadministration of udenafil and an a-blocker in patients with both BPH and ED was safe, and patients showed significant improvements in both LUTS and ED. This coadministration did not affect the incidence of cardiovascular side effects, and the other adverse events were almost minimal and selflimited. More advanced study should include the placebo control group and accurate monitoring of the hemodynamic parameters will have to be conducted.
